Akari Therapeutics (AKTX)
0.92
-0.02 (-1.81%)
At close: Mar 04, 2025, 9:45 AM
No 1D chart data available
| Bid | 0.9 |
| Market Cap | 5.59K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.72K |
| EPS (ttm) | -2.58 |
| PE Ratio (ttm) | -0.36 |
| Forward PE | -0.39 |
| Analyst | n/a |
| Ask | 0.94 |
| Volume | 9,498 |
| Avg. Volume (20D) | 47,360 |
| Open | 0.96 |
| Previous Close | 0.94 |
| Day's Range | 0.90 - 0.96 |
| 52-Week Range | 0.85 - 4.40 |
| Beta | 0.90 |
About AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous p...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 6, 2014
Employees 9
Stock Exchange NASDAQ
Ticker Symbol AKTX
Website https://www.akaritx.com
11 months ago
Akari Therapeutics shares are trading lower. The c...
Unlock content with
Pro Subscription
